The study aimed to assess how effective and safe enoxaparin, a low molecular weight heparin, is in preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after surgery.
Out of 1928 surgical patients, those receiving enoxaparin had significantly lower rates of DVT (2.9% vs. 6.1%) and PE (0.3% vs. 1.4%) during hospitalization compared to the control group, and this trend continued during follow-up.
The administration of enoxaparin was linked to slightly higher occurrences of minor and major bleeding compared to the control group, but the overall safety profile remained acceptable.*